Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)
Status:
Terminated
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
SSRI's are considered first-line treatments for GSP, however many patients continue to have
significant symptoms despite an adequate trial of an SSRI. Topiramate, a drug, which targets
the glutamate system in the brain, has been shown to improve symptoms of social phobia when
used on its own and has also been used as an additive treatment in other anxiety disorders.
This study will test the efficacy of adding topiramate to a subject's current SSRI in cases
of GSP which are considered to be treatment-resistant.
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation McMaster University
Collaborators:
Hamilton Health Sciences Corporation Janssen-Ortho Inc., Canada